Updated Jul 16, 2026
DIGIANDOMENICO ANTHONY has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $32K. Historical track record: 2/5 stars across 5 tracked purchases.
Anthony Digiandomenico is a corporate insider known for his roles as Director and Co-Founder of ENDRA Life Sciences Inc. He has been involved in the company's development of innovative ultrasound technology aimed at improving liver disease assessment.
| Role | Director |
|---|---|
| Notability | 20/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★☆☆☆ (2/5) |
|---|---|
| Total purchases tracked | 5 |
| Purchases with forward-return data | 5 |
| 30-day win rate | 6000% |
| 90-day win rate | 10000% |
| Avg 5-day return | +652.48% |
| Avg 30-day return | -27.21% |
| Avg 90-day return | +454.04% |
| Best 30-day return | +196.08% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-01-24 | NDRA | ENDRA Life Sciences Inc. | A — Grant or award | 60.3K | $0.00 | |
| 2025-10-10 | NDRA | ENDRA Life Sciences Inc. | A — Grant or award | 70.8K | $7.06 | $500K |
| 2025-06-11 | NDRA | ENDRA Life Sciences Inc. | A — Grant or award | 5.4K | $0.00 | |
| 2025-04-07 | MDBH | MDB Capital Holdings, LLC | P — Open-market purchase | 1.4K | $4.90 | $7K |
| 2024-12-23 | MDBH | MDB Capital Holdings, LLC | P — Open-market purchase | 355 | $6.25 | $2K |
| 2024-12-20 | MDBH | MDB Capital Holdings, LLC | P — Open-market purchase | 1.0K | $6.24 | $6K |
| 2024-12-20 | MDBH | MDB Capital Holdings, LLC | P — Open-market purchase | 1.0K | $6.20 | $6K |
| 2024-12-20 | MDBH | MDB Capital Holdings, LLC | P — Open-market purchase | 1.7K | $6.21 | $11K |
Anthony Digiandomenico is a corporate insider known for his roles as Director and Co-Founder of ENDRA Life Sciences Inc. He has been involved in the company's development of innovative ultrasound technology aimed at improving liver disease assessment.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 5 open-market purchases ($32K) and 0 open-market sales () across all tracked filings.
Across 5 tracked purchases, DIGIANDOMENICO ANTHONY averaged -27.2% avg 30-day return with a 6000% 30-day win rate. InsiderAlpha rates the track record at 2/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live DIGIANDOMENICO ANTHONY profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.